Abstract: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or ?? T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or ?? T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or ?? T cells and the number of the disease antigen-specific CD8+ CTLs and the ?? T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Abstract: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or ?? T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or ?? T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or ?? T cells and the number of the disease antigen-specific CD8+ CTLs and the ?? T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Abstract: A therapeutic method, which includes administering dendritic cells pulsed in vitro with a bisphosphonate-based bone metabolism improving drug, is provided. The dendritic cells may be capable of efficiently activating and/or proliferating ?? T-cells in vivo and/or in vitro. This can permit for easy proliferation of ?? T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize ?? T-cells.

Abstract: The present invention provides dendritic cells capable of efficiently activating and/or proliferating ?? T-cells in vivo and/or in vitro, pharmaceutical compositions comprising said dendritic cells, therapeutic methods and ?? T-cell culture methods utilizing said dendritic cells. By pulsing immature dendritic cells derived from peripheral blood monocytes with a bisphosphonate-based bone metabolism improving drug to enable the cells to activate ?? T-cells, and cultivating them with a cell subset containing ?? T-cells, ?? T-cells can be activated and/or proliferated. This allows for easy proliferation of ?? T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize ?? T-cells.

Abstract: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or ?? T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or ?? T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or ?? T cells and the number of the disease antigen-specific CD8+ CTLs and the ?? T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Abstract: The present invention provides dendritic cells capable of efficiently activating and/or proliferating ?? T-cells in vivo and/or in vitro, pharmaceutical compositions comprising said dendritic cells, therapeutic methods and ?? T-cell culture methods utilizing said dendritic cells. By pulsing immature dendritic cells derived from peripheral blood monocytes with a bisphosphonate-based bone metabolism improving drug to enable the cells to activate ?? T-cells, and cultivating them with a cell subset containing ?? T-cells, ?? T-cells can be activated and/or proliferated. This allows for easy proliferation of ?? T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize ?? T-cells.